Features
AI-enabled identification of antimicrobial peptides
Selective targeting against pathogenic bacteria
Minimal microbiome disruption
Topical therapeutic for Bacterial Vaginosis
Proprietary validation platform
Inspired by evolutionary milk proteins
Early-stage R&D for infectious diseases
Collaboration with UC Davis Foods For Health Institute
Focus on reducing antibiotic resistance
Preclinical-stage pipeline
Predictive AI models for protein-ligand interactions
Generative AI for novel molecule design
Built on Nobel Prize-winning AlphaFold system
Drug Design Engine combining predictive and generative AI
Digital biology simulation at scale
Interdisciplinary team of ML and pharma experts
Rapid iteration through AI-driven drug design engine
Partnership model for large-scale drug development
Collaboration with Novartis and Johnson & Johnson
US operations established in 2025
Series B funding in February 2026
